MedTrace Logo

COVID Vaccine Immunity in Kidney Transplant Recipients

NCT05387343 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-10-28

No results posted yet for this study

Summary

50 end-stage renal disease (ESRD) patients whom have had at least 2 doses of messenger ribonucleic acid (mRNA) vaccine, and undergoing transplantation at the University of Alabama at Birmingham (UAB) will be enrolled. The third mRNA vaccine will be given 3 months post transplant, and the 4th mRNA vaccine will be given 3 months following this. Blood samples will be collected and shipped to Viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.

Conditions

Interventions

DIAGNOSTIC_TEST

Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test

Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.

Sponsors & Collaborators

  • ViraCor Laboratories

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Graham C Towns, MD · University of Alabama at Birmingham

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2024-11-30
Completion
2024-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05387343 on ClinicalTrials.gov